Sciwind’s Verdiva Bio deal earnings could top $2.4 billion

10 January 2025

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea.

Recently-launched UK firm Verdiva is focused on developing innovative treatments for obesity and other cardiometabolic disorders.

The partnered portfolio under the collaboration includes the Phase II-ready once-weekly GLP-1 receptor agonist (RA) oral ecnoglutide, a once-weekly long-acting, oral amylin RA in IND-enabling studies and a subcutaneous long-acting injectable amylin RA that is also in IND-enabling studies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK